11 drugs likely to become blockbusters

The 11 drugs Clarivate expects to become blockbusters by 2024:

  1. Rimegepant (Biohaven Pharmaceutical) — designed to treat migraines.
  2. OMG-157 (Novartis) — designed to treat multiple sclerosis.
  3. Ozanimod (Celgene) — designed to treat multiple sclerosis.
  4. Vadadustat (Akebia Therapeutics/Mitsubishi Tanabe Pharma America/ Otsuka Pharmaceutical) — designed to treat anemia caused by chronic kidney disease.
  5. Valrox (BioMarin Pharmaceutical) — designed to treat hemophilia A.
  6. Filgotinib (Gilead Sciences) — designed to treat rheumatoid arthritis.
  7. Ryblesus (Novo Nordisk) — designed to treat Type 2 diabetes.
  8. Inclisiran (The Medicines Company) — designed to treat high cholesterol.
  9. Sacituzumab (Immunomedics) — designed to treat breast cancer.
  10. Enhertu (Astrazeneca/ Daiichi Sankyo) — designed to treat breast cancer.
  11. Liso-cel (Celgene) — designed to treat large B-cell lymphoma.

More: https://www.beckershospitalreview.com/pharmacy/11-drugs-likely-to-become-blockbusters.html